Study record
Fisetin for frailty and inflammation in older adults (AFFIRM / AFFIRM-LITE) — ongoing
Human RCT — disease/biomarker endpoint (ongoing, no results)
○ Evidence tier 2 — Human RCT — disease or biomarker endpoint
Record verify: primary source pending
| Design | Phase 2 double-blind randomized placebo-controlled (ongoing) |
| Registry | NCT03430037 |
| Citation status | verified via ClinicalTrials.gov v2 API: Mayo Clinic AFFIRM, Phase 2 randomized double-blind placebo-controlled, n=40 target, ENROLLING_BY_INVITATION as of 2026-05 — NO results published |
Five-qualifier claim
| Species / population | Older adults with frailty/multimorbidity (older women in AFFIRM; mixed cohort in AFFIRM-LITE). |
| Exposure, route, schedule | Oral fisetin 20 mg/kg/day for 2 days vs placebo (double-blind). |
| Comparator / duration | Randomized, placebo-controlled; short intermittent dosing. |
| Endpoint / numeric result | Endpoints are frailty (gait speed) and inflammatory markers. Status: enrolled/ongoing; no efficacy results published as of the search date. |
| What it did NOT establish | No results — the existence of the trial is not evidence of benefit. |
Interventions
Primary reference
https://clinicaltrials.gov/study/NCT03430037
Exact identifier to be confirmed against the primary record before publication where flagged above.